Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant versus split-course doxorubicin/cyclophosphamide with GM-CSF or G-CSF in locally advanced breast cancer
NL-OMON27543Suspended
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Feb 1999
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of doxorubicin, cyclophosphamide, sargramostim and filgrastim in breast cancer, sponsored by Amsterdam UMC, location VUmc. Started Feb 1999; status: suspended.
02
Drugs
doxorubicincyclophosphamidesargramostimfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON27543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27543.